LAWRENCE, Mass.--(BUSINESS WIRE)--[RUBIX LS], a minority-led life science research firm focusing on solutions to support minorities within clinical trials, announced today that it has formally launched its therapeutics division. While the industry remains challenged on supporting clinical research inclusion reeling from the devastating effects of the COVID-19 pandemic, Rubix is positioning its lead clinical trial platform to catalyze innovations for designing and developing therapeutics that will target conditions exhibited by minority and under-represented patient populations.
“We have invested in new facilities and clinical research capacity within the neurodegenerative and infectious disease health disciplines. These investments will allow Rubix LS to expand it’s growing product pipeline for decisive and inclusive health outcomes in various disease states in the coming months.” – Reginald Swift Ph.D, Founder & CEO of Rubix LS
About RUBIX LS
Rubix LS, founded in 2016, is a culturally-centric life science research firm that is building data, products, processes, and programs to wholly support the clinical research continuum that includes minority data sets in every phase of the life science development ecosystem. Enabling its the use of virtual clinical trials, it is bridging the scientific and operational expertise to design custom made solutions that enhance minority patient attention, recruitment, engagement, support, and education so that the life science industry can make better products for everyone. For more information about Rubix LS visit its website at www.rubixls.com
